Trump threatens 200% pharmaceutical tariffs
The president of the United States, Donald Trump, during a cabinet meeting at the White House in Washington, DC, USA,…
abbvie inc
Pfizer, Merck, J & J, others face scrutiny about the extension of fiscal lagoons
Johnson & Johnson's logo is shown in a monitor. Soup images | LIGHTROCKET | Getty images Two Democratic legislators pressed…
Trump's pharmaceutical rates feed new investments in the United States
JGI/Jamie Grill | Tetra images | Getty images A version of this article appeared for the first time in the…
We are lowering our target price of Bristol Myers despite a profit rate
Bristol Myers Squibb and Rosy Outlook's profits on Thursday did not solve persistent problems for actions. But it was enough,…
Trump says that pharmaceutical rates are arriving, the actions fall
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters The actions of drug…
Trump tariffs will challenge the big pharmaceuticals. Here are well positioned actions
Long Data Commercial Agreements have greatly protected the pharmaceutical industry of tariffs, but the objective of President Donald Trump to…
ABBVIE is the best weight player to lose weight
A sign is outside an ABBVie installation in Cambridge, Massachusetts. Brian Snyder | Reuters A version of this article appeared…
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…
We want to increase our ownership of a portfolio stock that just increased its dividend.
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…